Skip to content

Opus Genetics, Inc.: 10-Q filed 2012-11-08

What Opus Genetics, Inc. reported in its quarterly report filed 2012-11-08 (fiscal Q3 2012): 22 published measures, 73 facts as tagged in accession 0001140361-12-046272.

This filing

Form
10-Q (quarterly report)
Filed
2012-11-08
Fiscal period
fiscal Q3 2012
Accession
0001140361-12-046272 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Opus Genetics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-09-307,977,577USD
At 2011-12-3113,689,648USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-09-303,240,176USD
At 2011-12-312,983,518USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-09-304,737,401USD
At 2011-12-3110,706,130USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-09-307,379,999USD
At 2011-12-319,861,488USD
At 2011-09-3013,216,933USD
At 2010-12-3112,340,239USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-2,989,070USD92
2012-01-01 to 2012-09-30-6,171,266USD274
2001-03-19 to 2012-09-30-63,255,879USD4214
2011-07-01 to 2011-09-30-1,469,218USD92
2011-01-01 to 2011-09-30-11,734,231USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2001-03-19 to 2012-09-3066,178,583USD4214
2011-01-01 to 2011-09-3013,578,274USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-01-01 to 2012-09-303,064,592USD274
2001-03-19 to 2012-09-30-1,251,685USD4214
2011-01-01 to 2011-09-30-2,049,969USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-09-3062,379USD
At 2011-12-3194,542USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2012-01-01 to 2012-09-30202,537USD274
2001-03-19 to 2012-09-305,780,166USD4214
2011-01-01 to 2011-09-30513,255USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-1,799,779USD92
2012-01-01 to 2012-09-30-5,532,905USD274
2001-03-19 to 2012-09-30-67,507,045USD4214
2011-07-01 to 2011-09-30-3,355,059USD92
2011-01-01 to 2011-09-30-13,726,987USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-09-307,698,025USD
At 2011-12-3112,163,341USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2001-03-19 to 2012-09-3028,410USD4214

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2012-07-01 to 2012-09-301,799,779USD92
2012-01-01 to 2012-09-305,532,905USD274
2001-03-19 to 2012-09-3067,507,045USD4214
2011-07-01 to 2011-09-303,355,059USD92
2011-01-01 to 2011-09-3013,726,987USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-07-01 to 2012-09-301,066,245USD92
2012-01-01 to 2012-09-303,127,201USD274
2001-03-19 to 2012-09-3035,012,804USD4214
2011-07-01 to 2011-09-302,372,201USD92
2011-01-01 to 2011-09-3010,506,823USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-09-3095,345,656shares
At 2011-12-3195,345,656shares

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2012-09-30665,376USD
At 2011-12-31665,376USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2012-09-30602,997USD
At 2011-12-31570,834USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2012-09-30218,026USD
At 2011-12-31333,171USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-07-01 to 2012-09-30600,242USD92
2012-01-01 to 2012-09-302,071,008USD274
2001-03-19 to 2012-09-3029,418,003USD4214
2011-07-01 to 2011-09-30774,307USD92
2011-01-01 to 2011-09-302,811,097USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2012-07-01 to 2012-09-3010,721USD92
2012-01-01 to 2012-09-3032,163USD274
2011-07-01 to 2011-09-3010,127USD92
2011-01-01 to 2011-09-3034,904USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-1,189,291USD92
2012-01-01 to 2012-09-30-638,361USD274
2001-03-19 to 2012-09-304,251,166USD4214
2011-07-01 to 2011-09-301,885,841USD92
2011-01-01 to 2011-09-301,992,756USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2011-03-30 to 2011-03-3110,000,000USD2
2011-01-18 to 2011-01-193,926,397USD2
2010-06-29 to 2010-06-3010,000,000USD2
2009-10-22 to 2009-10-235,000,000USD2
2009-09-20 to 2009-09-213,371,340USD2
2009-06-04 to 2009-06-053,000,000USD2
2008-03-19 to 2008-03-20900,001USD2
2007-12-17 to 2007-12-186,800,023USD2

Inspect the source

Entity
Opus Genetics, Inc. / CIK 0001228627
Captured
2026-09-20T07:46:24.028Z
SEC response SHA-256
59b3f548361fa5c66fb8bd927bac9bc7dc8822bcce158860c7c4d77974af0a92

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001228627.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))